If amiodarone is risky, what safer rhythm-control options exist?

For your specific scenario – sick sinus syndrome, a pacemaker, and heart failure – catheter ablation is the best-supported option, but the data was never designed for it.

The evidence for ablation in heart failure with atrial fibrillation is solid on ejection fraction and hospitalization endpoints, but every major trial excluded your exact situation. The CAMTAF trial (2014) randomized 50 patients with heart failure and persistent atrial fibrillation to ablation or medical rate control [1]. Ablation improved left ventricular ejection fraction by 9 percentage points and cut BNP levels by more than half [1]. The 2019 meta-analysis of 18 trials (4,464 patients) found ablation reduced all-cause mortality by about 31% compared to medical therapy, though that result depends almost entirely on CASTLE-AF [3]. The same meta-analysis found ablation reduced cardiovascular hospitalizations by about 44% [3]. An earlier 2004 NEJM study in heart failure patients reported a 21-point average improvement in ejection fraction after ablation [2].

None of these trials enrolled patients with sick sinus syndrome or a pacemaker. The SAFE trial (2013) tested pacing strategies specifically in sick sinus syndrome with paroxysmal atrial fibrillation and found that right atrial septal pacing and continuous overdrive pacing did not reduce progression to persistent atrial fibrillation over three years [4]. The trial's annual rate of persistent atrial fibrillation was 8.3%, and pacing algorithms made no difference [4].

Amiodarone is the most effective drug for maintaining sinus rhythm but carries multisystem toxicity (thyroid, lung, liver) [6]. Dofetilide and sotalol are alternatives but require hospital initiation with QT monitoring and carry torsades risk [5, 6, 8]. In the SAFIRE-D trial (2000), dofetilide 500 mcg twice daily converted about 30% of patients with chronic atrial fibrillation and maintained sinus rhythm at one year in 58% [5]. The 2001 DIAMOND study showed dofetilide reduced heart failure hospitalizations in patients with reduced left ventricular function without increasing mortality [7].

My call: catheter ablation is the intervention with the strongest mechanistic rationale and the most replicated benefit for your combination of conditions, but the evidence base was never built for your specific situation. No trial has tested ablation against amiodarone optimization in a paced patient with sick sinus syndrome. The safer path is to review pacemaker settings first to minimize ventricular pacing, then consider ablation or a switch to dofetilide with in-hospital monitoring. Confidence: moderate for ablation's general benefit in heart failure with atrial fibrillation, low for its specific benefit in your situation.